Cellectis (CLLS) EBIT Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 32.96% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -29.67% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -50.81% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.47% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.35% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -12.10% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 55.96% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -2.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.41% |
| Dec 31, 2025 | -72.51% |
| Sep 30, 2025 | 31.89% |
| Jun 30, 2025 | 29.46% |
| Mar 31, 2025 | 21.43% |
| Dec 31, 2024 | -11.64% |
| Sep 30, 2024 | 36.65% |
| Jun 30, 2024 | 22.85% |
| Mar 31, 2024 | -1.63% |
| Dec 31, 2023 | 8.93% |
| Sep 30, 2023 | 11.03% |
| Jun 30, 2023 | 10.58% |
| Mar 31, 2023 | -53.63% |
| Dec 31, 2022 | 55.55% |
| Sep 30, 2022 | -0.87% |
| Jun 30, 2022 | 8.04% |
| Mar 31, 2022 | -8.13% |
| Dec 31, 2021 | 35.99% |
| Sep 30, 2021 | -13.60% |
| Jun 30, 2021 | -19.99% |
| Mar 31, 2021 | 7.19% |
| Dec 31, 2020 | -12.15% |
| Sep 30, 2020 | -4.53% |
| Jun 30, 2020 | -18.53% |
| Mar 31, 2020 | 39.75% |
| Dec 31, 2019 | -23.73% |
| Sep 30, 2019 | -27.37% |
| Jun 30, 2019 | -45.86% |
| Mar 31, 2019 | -0.89% |
| Dec 31, 2018 | -188.93% |
| Sep 30, 2018 | -24.56% |
| Jun 30, 2018 | -17.42% |
| Mar 31, 2018 | -83.66% |